Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arformoterol tartrate inhalation solution in COPD (Phase III, CTR20222650)
CTR20222650Phase 3Completed
- Sponsor
- Jiangsu Changtai Pharmaceutical
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of arformoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Jiangsu Changtai Pharmaceutical. Primary endpoint: Change from baseline in trough FEV1 at Week 12. Started Oct 2022; status: completed.
02
Drugs
arformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20222650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222650.